EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Leukoencephalopathy, a Frequent Complication After High‐Dose Methotrexate in Treatment of Osteosarcoma

Sandra Raimbault, Jean Louis Amegnizin, Audrey Longaud, Brice Fresneau iD, Nathalie Gaspar, Pablo Berlanga iD, Virginie Kieffer, Anne Maraval, Lucy Metayer, Christelle Dufour iD, Dominique Valteau-Couanet, Pierre Brugieres iD und 2 weitere

Pediatric Blood & Cancer · 2026

DOI: 10.1002/pbc.32104 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2026. Verfasst von Sandra Raimbault und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France. Hauptthemen laut MEDLINE: Methotrexate, Osteosarcoma, Bone Neoplasms, Leukoencephalopathies. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Methotrexate‐associated leukoencephalopathy is poorly documented in osteosarcoma. Since 2007, our institution has monitored osteosarcoma patients with sequential magnetic resonance imaging (MRI) and neuropsychological evaluations during treatment and follow‐up.

Methods

We analyzed data from consecutive osteosarcoma patients younger than 25 years enrolled at Gustave Roussy in the OS2006 study (2007–2015) and treated with high‐dose methotrexate (MTX) and etoposide–ifosfamide. Eligible patients received four or more MTX courses and at least one brain MRI. MTX‐related neurotoxicity was defined as neurological symptoms attributed to MTX after excluding other causes.

Results

MTX‐related neurotoxicity occurred in seven (13%) of 53 eligible patients. Additionally, 12 had severe depression, nine reported attention/memory deficits, and 25 had headaches during MTX infusion. Acute symptoms resolved in all but one. Forty‐nine patients had an MRI during treatment, and 47 after. Leukoencephalopathy was found in 44 (83%): Grade 1 in six, Grade 2 in 15, and Grade 3 in 23. Grade 2–3 leukoencephalopathy was more frequent in patients with severe depression ( p = 0.02) and those receiving more than 12 MTX courses ( p = 0.03); no association was found with age, sex, MTX‐related neurotoxicity, or cognitive complaints. Among 24 patients with MRI ≥3 years post‐treatment, 20 still showed leukoencephalopathy (12 Grade 1, eight Grade 2). Neurocognitive evaluations showed IQ scores consistent with norms, except for lower processing speed, which improved post‐treatment. At last follow‐up (median 8.5 years), most patients had integrated into school or work.

Conclusion

MTX‐associated leukoencephalopathy is frequent in osteosarcoma, even in asymptomatic patients, and often persists after treatment. Serious neurocognitive sequelae appear uncommon, but long‐term cognitive monitoring is essential to detect subtle deficits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MethotrexateOsteosarcomaBone NeoplasmsLeukoencephalopathiesAntineoplastic Combined Chemotherapy ProtocolsAntimetabolites, AntineoplasticHumansMaleFemaleAdolescentChildYoung AdultFollow-Up StudiesAdultMagnetic Resonance ImagingPrognosisEtoposideIfosfamideChild, Preschool

Stichwörter der Autor:innen

leukoencephalopathymethotrexateneurotoxicityosteosarcoma

Substanzen

MethotrexateEtoposideIfosfamideAntimetabolites, Antineoplastic

Autor:innen und Institutionen

  • Department of Children and Adolescent Oncology, Gustave Roussy Cancer Center, Villejuif, France.
  • Department of Pediatric and AYA Oncology, Centre Oscar Lambret, Lille, France.
  • Department of Neuroradiology, Henri Mondor University Hospital, Creteil, France.
  • INSERM U1018 CESP, Radiation Epidemiology Team, Paris-Saclay University, Villejuif, France.
  • Inserm U1015, Paris Saclay University, Villejuif, France.
  • Rehabilitation Department for Children with Acquired Brain Injury, Saint Maurice Hospitals, Saint Maurice, France.

ORCID-Profile: Brice Fresneau, Pablo Berlanga, Christelle Dufour, Pierre Brugieres

Zitieren

APA

Raimbault, S., Amegnizin, J. L., Longaud, A., Fresneau, B., Gaspar, N., Berlanga, P., Kieffer, V., Maraval, A., Metayer, L., Dufour, C., Valteau-Couanet, D., Brugieres, P., Bapst, B., & Brugieres, L. (2026). Leukoencephalopathy, a Frequent Complication After High‐Dose Methotrexate in Treatment of Osteosarcoma. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.32104

Vancouver

Raimbault S, Amegnizin JL, Longaud A, Fresneau B, Gaspar N, Berlanga P, et al. Leukoencephalopathy, a Frequent Complication After High‐Dose Methotrexate in Treatment of Osteosarcoma. Pediatric Blood & Cancer. 2026. doi:10.1002/pbc.32104

BibTeX
@article{Raimbault2026,
  author = {Raimbault, Sandra and Amegnizin, Jean Louis and Longaud, Audrey and Fresneau, Brice and Gaspar, Nathalie and Berlanga, Pablo and Kieffer, Virginie and Maraval, Anne and Metayer, Lucy and Dufour, Christelle and Valteau-Couanet, Dominique and Brugieres, Pierre and Bapst, Blanche and Brugieres, Laurence},
  title = {Leukoencephalopathy, a Frequent Complication After High‐Dose Methotrexate in Treatment of Osteosarcoma},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  doi = {10.1002/pbc.32104}
}
Kostenlos starten →